Ubs Asset Management Americas Inc Kymera Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 428,529 shares of KYMR stock, worth $19 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
428,529
Previous 433,573
1.16%
Holding current value
$19 Million
Previous $12.9 Million
56.71%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding KYMR
# of Institutions
183Shares Held
64.3MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$295 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$266 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$229 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$217 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$211 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.43B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...